- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06148649
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Multicenter, Randomised, Paralleled, Placebo-controlled (Double-blind) and Active Drug-controlled (Open) Study to Investigate Efficacy and Safety of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
This is a multicenter, randomized, parallel, placebo- and active comparator-controlled phase 2 trial to evaluate the efficacy, safety, pharmacokinetics and immunogenicity in subjects with T2DM.
Patients treated with diet and exercise alone, or in combination with stable metformin monotherapy (≥1500 mg/day or maximum tolerated dose ≥1000 mg/ day.), will be enrolled. Approximately 225 participants will be randomized. The study includes four stages: screening period (up to 2 weeks), lead-in period (2 weeks), treatment period (12 weeks) and safety follow-up period (3 weeks after treatment).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: linong Ji, Doctor
- Phone Number: 13910978815
- Email: jiln@bjmu.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Not yet recruiting
- Peking University People's Hospital
-
Contact:
- Linong Ji, Doctor
- Phone Number: 13910978815
- Email: jiln@bimu.edu.cn
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Recruiting
- Shijiazhuang People's Hospital
-
Contact:
- Zhigang Zhao
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients 18 to 75 years of age, inclusive.
- Have T2DM for at least 3 months before screening based on the disease diagnostic criteria (WHO 1999).
- Have an HbA1c value of ≥7.5% and ≤10.5%, fasting blood-glucose ≤13.9 mmoL/L, at screening and visit 3.
Exclusion Criteria:
- Have type 1 diabetes mellitus.
- Have had ≥1 episode of severe hypoglycemia within 6 months before screening, or history of recurrent hypoglycemia (history of hypoglycemia more than 3 times in 3 months).
- Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level >2.5 times the upper limit of the reference range at screening.
- Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) at screening.
- Have serum calcitonin ≥20 ng/L at screening.
- Fasted triglycerides > 5.7 mmol/L at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HEC88473 dose1
T2DM subjects, receiving a weekly dose of HEC88473 dose1
|
T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
|
Experimental: HEC88473 dose2
T2DM subjects, receiving a weekly dose of HEC88473 dose2
|
T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
|
Experimental: HEC88473 dose3
T2DM subjects, receiving a weekly dose of HEC88473 dose3
|
T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
|
Placebo Comparator: Placebo
T2DM subjects, receiving a weekly dose of placebo
|
T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
|
Active Comparator: Dulaglutide
T2DM subjects, receiving a weekly dose of dulaglutide
|
T2DM subjects, receiving a weekly dose of HEC88473, placebo or dulaglutide.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of HbA1c at week 12
Time Frame: Baseline to week 12
|
HbA1c
|
Baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of weight at week 12
Time Frame: Baseline to week 12
|
weight
|
Baseline to week 12
|
Change from baseline of fasting blood-glucose at week 12
Time Frame: Baseline to week 12
|
fasting blood-glucose
|
Baseline to week 12
|
Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Baseline to week 15
|
Adverse Events (AEs) and Serious Adverse Events (SAEs)
|
Baseline to week 15
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEC88473-DM-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... and other collaboratorsCompletedType 2 Diabetes Mellitus
Clinical Trials on HEC88473, Placebo, Dulaglutide
-
Dongguan HEC Biopharmaceutical R&D Co., Ltd.CompletedObesity | Healthy Subjects | T2DM (Type 2 Diabetes Mellitus)China
-
Dongguan HEC Biopharmaceutical R&D Co., Ltd.CompletedThe Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy SubjectsNon-alcoholic SteatohepatitisAustralia
-
Fujian Shengdi Pharmaceutical Co., Ltd.Recruiting
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Not yet recruiting
-
Eli Lilly and CompanyCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruiting
-
Hospices Civils de LyonCompletedAdult Subjects With Type1Diabetes and Insulin MicrosecretionFrance
-
Vanderbilt University Medical CenterNashville VA Medical CenterRecruitingChronic Kidney DiseasesUnited States
-
Shanghai Zhongshan HospitalCompletedType 2 DiabetesChina
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States